Compare ADMA Biologics Inc (ADMA) vs Mercadolibre Inc (MELI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Mercadolibre Inc — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while Mercadolibre Inc trades at $1,793.25 (market cap $91.94B). The key difference: Mercadolibre Inc is far larger — about 43.2× ADMA Biologics Inc's market cap, and Mercadolibre Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | MELI | |
|---|---|---|
Market Cap | $2.13B | $91.94B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $2.51K |
52-Week Low | $7.60 | $1.55K |
Enterprise Value | $2.20B | $98.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
MercadoLibre (MELI) trades at $1,813.61, up 2.85% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical outlook with robust revenue growth of 49% in Q1 2026 and expanding cash flow generation. Analyst consensus remains strongly positive with a $2,230 price target, though margin compression from aggressive investments presents near-term challenges.
MELI offers significant growth potential as Latin America's e-commerce leader, but faces execution risks from margin pressure and legal investigations. The stock trades at premium valuations (P/E 47.66) requiring sustained high growth to justify current levels. Institutional support remains strong with 71.9% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
